<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cunningham, Muriel</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Couturaud, Francis</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Risk Factors for Recurrent Venous Thromboembolism Revealed in PADIS-PE Trial</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2015</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2015-08-10 10:58:07</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">8-9</style></pages><abstract><style  face="normal" font="default" size="100%">The objective of the PADIS-PE study was to determine whether patients with 1 episode of unprovoked pulmonary embolism would benefit from an additional 18 months of oral anticoagulant treatment. Age, residual perfusion defects, and residual deep vein thrombosis were found to be independent risk factors associated with recurrent venous thromboembolism.</style></abstract><number><style face="normal" font="default" size="100%">21</style></number><volume><style face="normal" font="default" size="100%">15</style></volume></record></records></xml>